Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B - Asset Resilience Ratio
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B (900904) has an Asset Resilience Ratio of 1.33% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 900904 liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2024)
This chart shows how Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B's Asset Resilience Ratio has changed over time. See Shanghai Shenqi Pharmaceutical Investmen book value and equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Shanghai Shenqi Pharmaceutical Investmen market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $40.00 Million | 1.33% |
| Total Liquid Assets | $40.00 Million | 1.33% |
Asset Resilience Insights
- Limited Liquidity: Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B maintains only 1.33% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B Industry Peers by Asset Resilience Ratio
Compare Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Roche Holding AG
SW:ROG |
Drug Manufacturers - General | 15.37% |
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 7.18% |
|
Novartis AG
SW:NOVN |
Drug Manufacturers - General | 10.04% |
|
Novartis AG
MX:NVSN |
Drug Manufacturers - General | 0.09% |
|
CSPC Pharmaceutical Group Limited
F:CVG |
Drug Manufacturers - General | 4.64% |
|
Virbac SA
PA:VIRP |
Drug Manufacturers - General | 0.23% |
|
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SHE:300357 |
Drug Manufacturers - General | 9.91% |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771 |
Drug Manufacturers - General | 40.02% |
Annual Asset Resilience Ratio for Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B (2023–2024)
The table below shows the annual Asset Resilience Ratio data for Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.67% | $20.87 Million | $3.12 Billion | +0.03pp |
| 2023-12-31 | 0.64% | $20.90 Million | $3.28 Billion | -- |
About Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd., together with its subsidiaries, operates as a pharmaceutical manufacturing holding investment company in China. The company engages in the research and development, and production of anti-tumor, cardiovascular, cerebrovascular, rheumatism bone pain, tonic and sedative, cold and cough, anti-fungal, gynecology, and other treatment fiel… Read more